セボフルラン市場の2032年までの予測：製品、製剤、流通チャネル、用途、エンドユーザー、地域別の世界分析

Stratistics MRCによると、セボフルランの世界市場は2025年に4億7,610万米ドルを占め、予測期間中にCAGR 6.5％で成長し、2032年には7億3,990万米ドルに達すると予想されています。

セボフルランは揮発性の吸入麻酔薬で、全身麻酔の導入と維持に広く使用されています。無色で不燃性の液体であり、甘い香りがするため、小児や成人の患者に最適です。速やかな麻酔開始と回復で知られるセボフルランは、気道への刺激を最小限に抑え、スムーズな麻酔導入を可能にします。血液ガス分配係数が低いため、麻酔深度を素早く調整できます。一般に忍容性は高いが、用量依存性の低血圧やまれに腎毒性を引き起こすことがあります。

2021年に発表されたWorld Journal of Surgeryによると、インドでは人口の外科的要求を満たすために3646件の手術が行われました。

増加する外科手術

世界の外科手術件数の増加が、セボフルラン市場の大幅な成長を後押ししています。セボフルランは人気のある吸入麻酔薬で、その迅速な導入と回復時間により、病院や外来手術センターで使用されています。慢性疾患の発生率の増加、侵襲性の低い手術の改善、より大規模な医療システムの開発によっても需要が増加しています。現代の麻酔法におけるセボフルランの重要な機能は、高齢化による外科手術の必要性の高まりによる市場の拡大によってさらに裏付けられています。

代替品に比べ高コスト

代替麻酔薬と比較してセボフルランは高コストであることが、市場成長の大きな妨げとなっています。特にコストに敏感な地域のヘルスケア施設は、イソフルランやデスフルランのような低コストの代替品を選ぶ可能性があり、セボフルランの採用が制限されます。このコスト障壁は、特に新興国市場における調達の意思決定に影響を与え、全体的な需要を減少させる。さらに、価格に敏感な病院や診療所ではセボフルランの使用が制限される可能性があり、メーカーの売上高や収益成長に影響を与えます。

麻酔技術の進歩

麻酔技術の進歩は、患者の安全性、正確性、手術の効率性を高め、市場の大きな成長を促進しています。自動麻酔デリバリー、リアルタイムモニタリング、低流量技術などの革新は、セボフルランの使用量を最適化し、無駄や副作用を減らします。低侵襲手術の増加や気化器の改良が需要をさらに押し上げています。さらに、薬物動態の向上と回復プロファイルの改善により、セボフルランは麻酔医に好まれる選択肢となっています。これらの進歩は総体的に市場拡大を後押しし、世界中でより安全で効果的な麻酔投与を可能にしています。

潜在的副作用

セボフルラン市場は、規制上の制限、サプライチェーンの混乱、健康上の懸念による潜在的な悪影響に直面しています。揮発性麻酔薬に関する厳しい環境規制が市場拡大の妨げとなります。原材料の不足を含むサプライチェーンの不安定性は、生産と価格設定に影響を及ぼします。さらに、小児や高齢者の神経毒性に対する懸念が安全性の問題を引き起こし、採用率の低下につながります。代替麻酔薬との競合の激化や、全身静脈麻酔（TIVA）への嗜好の高まりが、市場の成長と収益性をさらに制限しています。

COVID-19の影響：

COVID-19の流行はセボフルラン市場にさまざまな影響を与えました。施錠により待機手術が減少した一方で、セボフルランの需要は重症患者、特にCOVID-19患者の人工呼吸で急増しました。サプライチェーンの混乱と病院リソースの再配分は当初市場の成長を鈍化させたが、パンデミック後の回復、外科手術の増加、ヘルスケアインフラの改善により、業界全体で需要が力強く回復しています。

予測期間中、病院セグメントが最大になる見込み

病院施設は外科手術の麻酔薬の主要ユーザーであるため、予測期間中、病院セグメントが最大の市場シェアを占めると予想されます。手術件数の増加、ヘルスケアインフラの整備、麻酔技術の進歩により、病院はセボフルランの需要を押し上げています。さらに、外科的介入を必要とする慢性疾患の有病率が高まっていることも、市場の成長を後押ししています。このセグメントは、その有効性、安全性プロファイル、全身麻酔における広範な使用により、強力な採用の恩恵を受けており、市場拡大への好影響を強めています。

予測期間中、高純度セボフルランセグメントのCAGRが最も高くなる見込み

予測期間中、高純度セボフルランセグメントは、麻酔用途における優れた有効性、安全性、副作用の低減により、最も高い成長率を示すと予測されます。外科手術の増加や低侵襲治療に対する需要の高まりに伴い、病院や診療所では患者の予後を改善するために高純度製剤が優先されています。さらに、厳格な規制基準と医薬品製造の進歩が一貫した品質を保証しており、市場導入をさらに後押ししています。

最大のシェアを占める地域

予測期間中、北米地域は外科手術の増加、麻酔薬の技術開発、ヘルスケア支出の増加により、最大の市場シェアを占めると予想されます。セボフルランは、その有効性、回復期間の短さ、副作用の少なさから、吸入麻酔薬として推奨されています。高齢化社会と慢性疾患の増加も需要に拍車をかけています。その人気は、麻酔薬投与技術の継続的な研究開発によってさらに後押しされています。この市場の拡大は、この地域の最先端ヘルスケア・インフラに拍車をかけ、患者により良い結果をもたらすことを保証しています。

CAGRが最も高い地域：

予測期間中、アジア太平洋地域が最も高いCAGRを示すと予測されます。これは、外科手術の増加、ヘルスケアインフラの成長、麻酔薬における技術的ブレークスルーのためです。より安全で効果的な吸入麻酔薬を提供することで、市場は患者の転帰を改善しています。高齢化、医療ツーリズムの増加、病院開発によって需要はさらに高まっています。セボフルランは、外科手術の有効性と一般的なヘルスケア水準を向上させる大きな要因であり、ヘルスケアへのアクセスを改善するための政府プログラムも市場の成長を支えています。

無料のカスタマイズサービス

本レポートをご購読のお客様には、以下の無料カスタマイズオプションのいずれかをご利用いただけます：

• 企業プロファイル
  • 追加市場企業の包括的プロファイリング（3社まで）
  • 主要企業のSWOT分析（3社まで）
• 地域セグメンテーション
  • 顧客の関心に応じた主要国の市場推計・予測・CAGR（注：フィージビリティチェックによる）
• 競合ベンチマーキング
  • 製品ポートフォリオ、地理的プレゼンス、戦略的提携に基づく主要企業のベンチマーキング

目次

第1章 エグゼクティブサマリー

第2章 序文

• 概要
• ステークホルダー
• 調査範囲
• 調査手法
  • データマイニング
  • データ分析
  • データ検証
  • 調査アプローチ
• 調査資料
  • 1次調査資料
  • 2次調査情報源
  • 前提条件

第3章 市場動向分析

• 促進要因
• 抑制要因
• 機会
• 脅威
• 製品分析
• 用途分析
• エンドユーザー分析
• 新興市場
• COVID-19の影響

第4章 ポーターのファイブフォース分析

• 供給企業の交渉力
• 買い手の交渉力
• 代替品の脅威
• 新規参入業者の脅威
• 競争企業間の敵対関係

第5章 世界のセボフルラン市場：製品別

• ジェネリックセボフルラン
• ブランドセボフルラン

第6章 世界のセボフルラン市場：製剤別

• 標準純度セボフルラン
• 高純度セボフルラン

第7章 世界のセボフルラン市場：流通チャネル別

• 直接販売
• 販売代理店/卸売業者
• オンライン薬局
• 小売薬局

第8章 世界のセボフルラン市場：用途別

• 麻酔の導入
• 麻酔の維持

第9章 世界のセボフルラン市場：エンドユーザー別

• 病院
• 外来手術センター（ASC）
• 専門クリニック
• その他のヘルスケア施設

第10章 世界のセボフルラン市場：地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • イタリア
  • フランス
  • スペイン
  • その他欧州
• アジア太平洋
  • 日本
  • 中国
  • インド
  • オーストラリア
  • ニュージーランド
  • 韓国
  • その他アジア太平洋地域
• 南米
  • アルゼンチン
  • ブラジル
  • チリ
  • その他南米
• 中東・アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • カタール
  • 南アフリカ
  • その他中東とアフリカ

第11章 主な発展

• 契約、パートナーシップ、コラボレーション、ジョイントベンチャー
• 買収と合併
• 新製品発売
• 事業拡大
• その他の主要戦略

第12章 企業プロファイリング

• AbbVie Inc.
• Accord Healthcare
• AstraZeneca
• Baxter International Inc.
• Beijing Zizhu Pharmaceutical Co., Ltd.
• Endo International plc
• Fresenius Kabi AG
• Hikma Pharmaceuticals PLC
• Hospira Inc.
• Jiangsu Hengrui Pharmaceuticals Co., Ltd.
• Lunan Pharmaceutical Group Co., Ltd.
• Maruishi Pharmaceutical Co., Ltd.
• Merck KGaA
• Piramal Critical Care
• Shandong Keyuan Pharmaceutical Co., Ltd.
• Shanghai Huayuan Ethylene Co., Ltd.
• Troikaa Pharmaceuticals Ltd. .

List of Tables

• Table 1 Global Sevoflurane Market Outlook, By Region (2024-2032) ($MN)
• Table 2 Global Sevoflurane Market Outlook, By Product (2024-2032) ($MN)
• Table 3 Global Sevoflurane Market Outlook, By Generic Sevoflurane (2024-2032) ($MN)
• Table 4 Global Sevoflurane Market Outlook, By Branded Sevoflurane (2024-2032) ($MN)
• Table 5 Global Sevoflurane Market Outlook, By Formulation (2024-2032) ($MN)
• Table 6 Global Sevoflurane Market Outlook, By Standard Purity Sevoflurane (2024-2032) ($MN)
• Table 7 Global Sevoflurane Market Outlook, By High Purity Sevoflurane (2024-2032) ($MN)
• Table 8 Global Sevoflurane Market Outlook, By Distribution Channel (2024-2032) ($MN)
• Table 9 Global Sevoflurane Market Outlook, By Direct Sales (2024-2032) ($MN)
• Table 10 Global Sevoflurane Market Outlook, By Distributors/Wholesalers (2024-2032) ($MN)
• Table 11 Global Sevoflurane Market Outlook, By Online Pharmacies (2024-2032) ($MN)
• Table 12 Global Sevoflurane Market Outlook, By Retail Pharmacies (2024-2032) ($MN)
• Table 13 Global Sevoflurane Market Outlook, By Application (2024-2032) ($MN)
• Table 14 Global Sevoflurane Market Outlook, By Induction of Anesthesia (2024-2032) ($MN)
• Table 15 Global Sevoflurane Market Outlook, By Maintenance of Anesthesia (2024-2032) ($MN)
• Table 16 Global Sevoflurane Market Outlook, By End User (2024-2032) ($MN)
• Table 17 Global Sevoflurane Market Outlook, By Hospitals (2024-2032) ($MN)
• Table 18 Global Sevoflurane Market Outlook, By Ambulatory Surgical Centers (ASCs) (2024-2032) ($MN)
• Table 19 Global Sevoflurane Market Outlook, By Specialty Clinics (2024-2032) ($MN)
• Table 20 Global Sevoflurane Market Outlook, By Other Healthcare Facilities (2024-2032) ($MN)
• Table 21 North America Sevoflurane Market Outlook, By Country (2024-2032) ($MN)
• Table 22 North America Sevoflurane Market Outlook, By Product (2024-2032) ($MN)
• Table 23 North America Sevoflurane Market Outlook, By Generic Sevoflurane (2024-2032) ($MN)
• Table 24 North America Sevoflurane Market Outlook, By Branded Sevoflurane (2024-2032) ($MN)
• Table 25 North America Sevoflurane Market Outlook, By Formulation (2024-2032) ($MN)
• Table 26 North America Sevoflurane Market Outlook, By Standard Purity Sevoflurane (2024-2032) ($MN)
• Table 27 North America Sevoflurane Market Outlook, By High Purity Sevoflurane (2024-2032) ($MN)
• Table 28 North America Sevoflurane Market Outlook, By Distribution Channel (2024-2032) ($MN)
• Table 29 North America Sevoflurane Market Outlook, By Direct Sales (2024-2032) ($MN)
• Table 30 North America Sevoflurane Market Outlook, By Distributors/Wholesalers (2024-2032) ($MN)
• Table 31 North America Sevoflurane Market Outlook, By Online Pharmacies (2024-2032) ($MN)
• Table 32 North America Sevoflurane Market Outlook, By Retail Pharmacies (2024-2032) ($MN)
• Table 33 North America Sevoflurane Market Outlook, By Application (2024-2032) ($MN)
• Table 34 North America Sevoflurane Market Outlook, By Induction of Anesthesia (2024-2032) ($MN)
• Table 35 North America Sevoflurane Market Outlook, By Maintenance of Anesthesia (2024-2032) ($MN)
• Table 36 North America Sevoflurane Market Outlook, By End User (2024-2032) ($MN)
• Table 37 North America Sevoflurane Market Outlook, By Hospitals (2024-2032) ($MN)
• Table 38 North America Sevoflurane Market Outlook, By Ambulatory Surgical Centers (ASCs) (2024-2032) ($MN)
• Table 39 North America Sevoflurane Market Outlook, By Specialty Clinics (2024-2032) ($MN)
• Table 40 North America Sevoflurane Market Outlook, By Other Healthcare Facilities (2024-2032) ($MN)
• Table 41 Europe Sevoflurane Market Outlook, By Country (2024-2032) ($MN)
• Table 42 Europe Sevoflurane Market Outlook, By Product (2024-2032) ($MN)
• Table 43 Europe Sevoflurane Market Outlook, By Generic Sevoflurane (2024-2032) ($MN)
• Table 44 Europe Sevoflurane Market Outlook, By Branded Sevoflurane (2024-2032) ($MN)
• Table 45 Europe Sevoflurane Market Outlook, By Formulation (2024-2032) ($MN)
• Table 46 Europe Sevoflurane Market Outlook, By Standard Purity Sevoflurane (2024-2032) ($MN)
• Table 47 Europe Sevoflurane Market Outlook, By High Purity Sevoflurane (2024-2032) ($MN)
• Table 48 Europe Sevoflurane Market Outlook, By Distribution Channel (2024-2032) ($MN)
• Table 49 Europe Sevoflurane Market Outlook, By Direct Sales (2024-2032) ($MN)
• Table 50 Europe Sevoflurane Market Outlook, By Distributors/Wholesalers (2024-2032) ($MN)
• Table 51 Europe Sevoflurane Market Outlook, By Online Pharmacies (2024-2032) ($MN)
• Table 52 Europe Sevoflurane Market Outlook, By Retail Pharmacies (2024-2032) ($MN)
• Table 53 Europe Sevoflurane Market Outlook, By Application (2024-2032) ($MN)
• Table 54 Europe Sevoflurane Market Outlook, By Induction of Anesthesia (2024-2032) ($MN)
• Table 55 Europe Sevoflurane Market Outlook, By Maintenance of Anesthesia (2024-2032) ($MN)
• Table 56 Europe Sevoflurane Market Outlook, By End User (2024-2032) ($MN)
• Table 57 Europe Sevoflurane Market Outlook, By Hospitals (2024-2032) ($MN)
• Table 58 Europe Sevoflurane Market Outlook, By Ambulatory Surgical Centers (ASCs) (2024-2032) ($MN)
• Table 59 Europe Sevoflurane Market Outlook, By Specialty Clinics (2024-2032) ($MN)
• Table 60 Europe Sevoflurane Market Outlook, By Other Healthcare Facilities (2024-2032) ($MN)
• Table 61 Asia Pacific Sevoflurane Market Outlook, By Country (2024-2032) ($MN)
• Table 62 Asia Pacific Sevoflurane Market Outlook, By Product (2024-2032) ($MN)
• Table 63 Asia Pacific Sevoflurane Market Outlook, By Generic Sevoflurane (2024-2032) ($MN)
• Table 64 Asia Pacific Sevoflurane Market Outlook, By Branded Sevoflurane (2024-2032) ($MN)
• Table 65 Asia Pacific Sevoflurane Market Outlook, By Formulation (2024-2032) ($MN)
• Table 66 Asia Pacific Sevoflurane Market Outlook, By Standard Purity Sevoflurane (2024-2032) ($MN)
• Table 67 Asia Pacific Sevoflurane Market Outlook, By High Purity Sevoflurane (2024-2032) ($MN)
• Table 68 Asia Pacific Sevoflurane Market Outlook, By Distribution Channel (2024-2032) ($MN)
• Table 69 Asia Pacific Sevoflurane Market Outlook, By Direct Sales (2024-2032) ($MN)
• Table 70 Asia Pacific Sevoflurane Market Outlook, By Distributors/Wholesalers (2024-2032) ($MN)
• Table 71 Asia Pacific Sevoflurane Market Outlook, By Online Pharmacies (2024-2032) ($MN)
• Table 72 Asia Pacific Sevoflurane Market Outlook, By Retail Pharmacies (2024-2032) ($MN)
• Table 73 Asia Pacific Sevoflurane Market Outlook, By Application (2024-2032) ($MN)
• Table 74 Asia Pacific Sevoflurane Market Outlook, By Induction of Anesthesia (2024-2032) ($MN)
• Table 75 Asia Pacific Sevoflurane Market Outlook, By Maintenance of Anesthesia (2024-2032) ($MN)
• Table 76 Asia Pacific Sevoflurane Market Outlook, By End User (2024-2032) ($MN)
• Table 77 Asia Pacific Sevoflurane Market Outlook, By Hospitals (2024-2032) ($MN)
• Table 78 Asia Pacific Sevoflurane Market Outlook, By Ambulatory Surgical Centers (ASCs) (2024-2032) ($MN)
• Table 79 Asia Pacific Sevoflurane Market Outlook, By Specialty Clinics (2024-2032) ($MN)
• Table 80 Asia Pacific Sevoflurane Market Outlook, By Other Healthcare Facilities (2024-2032) ($MN)
• Table 81 South America Sevoflurane Market Outlook, By Country (2024-2032) ($MN)
• Table 82 South America Sevoflurane Market Outlook, By Product (2024-2032) ($MN)
• Table 83 South America Sevoflurane Market Outlook, By Generic Sevoflurane (2024-2032) ($MN)
• Table 84 South America Sevoflurane Market Outlook, By Branded Sevoflurane (2024-2032) ($MN)
• Table 85 South America Sevoflurane Market Outlook, By Formulation (2024-2032) ($MN)
• Table 86 South America Sevoflurane Market Outlook, By Standard Purity Sevoflurane (2024-2032) ($MN)
• Table 87 South America Sevoflurane Market Outlook, By High Purity Sevoflurane (2024-2032) ($MN)
• Table 88 South America Sevoflurane Market Outlook, By Distribution Channel (2024-2032) ($MN)
• Table 89 South America Sevoflurane Market Outlook, By Direct Sales (2024-2032) ($MN)
• Table 90 South America Sevoflurane Market Outlook, By Distributors/Wholesalers (2024-2032) ($MN)
• Table 91 South America Sevoflurane Market Outlook, By Online Pharmacies (2024-2032) ($MN)
• Table 92 South America Sevoflurane Market Outlook, By Retail Pharmacies (2024-2032) ($MN)
• Table 93 South America Sevoflurane Market Outlook, By Application (2024-2032) ($MN)
• Table 94 South America Sevoflurane Market Outlook, By Induction of Anesthesia (2024-2032) ($MN)
• Table 95 South America Sevoflurane Market Outlook, By Maintenance of Anesthesia (2024-2032) ($MN)
• Table 96 South America Sevoflurane Market Outlook, By End User (2024-2032) ($MN)
• Table 97 South America Sevoflurane Market Outlook, By Hospitals (2024-2032) ($MN)
• Table 98 South America Sevoflurane Market Outlook, By Ambulatory Surgical Centers (ASCs) (2024-2032) ($MN)
• Table 99 South America Sevoflurane Market Outlook, By Specialty Clinics (2024-2032) ($MN)
• Table 100 South America Sevoflurane Market Outlook, By Other Healthcare Facilities (2024-2032) ($MN)
• Table 101 Middle East & Africa Sevoflurane Market Outlook, By Country (2024-2032) ($MN)
• Table 102 Middle East & Africa Sevoflurane Market Outlook, By Product (2024-2032) ($MN)
• Table 103 Middle East & Africa Sevoflurane Market Outlook, By Generic Sevoflurane (2024-2032) ($MN)
• Table 104 Middle East & Africa Sevoflurane Market Outlook, By Branded Sevoflurane (2024-2032) ($MN)
• Table 105 Middle East & Africa Sevoflurane Market Outlook, By Formulation (2024-2032) ($MN)
• Table 106 Middle East & Africa Sevoflurane Market Outlook, By Standard Purity Sevoflurane (2024-2032) ($MN)
• Table 107 Middle East & Africa Sevoflurane Market Outlook, By High Purity Sevoflurane (2024-2032) ($MN)
• Table 108 Middle East & Africa Sevoflurane Market Outlook, By Distribution Channel (2024-2032) ($MN)
• Table 109 Middle East & Africa Sevoflurane Market Outlook, By Direct Sales (2024-2032) ($MN)
• Table 110 Middle East & Africa Sevoflurane Market Outlook, By Distributors/Wholesalers (2024-2032) ($MN)
• Table 111 Middle East & Africa Sevoflurane Market Outlook, By Online Pharmacies (2024-2032) ($MN)
• Table 112 Middle East & Africa Sevoflurane Market Outlook, By Retail Pharmacies (2024-2032) ($MN)
• Table 113 Middle East & Africa Sevoflurane Market Outlook, By Application (2024-2032) ($MN)
• Table 114 Middle East & Africa Sevoflurane Market Outlook, By Induction of Anesthesia (2024-2032) ($MN)
• Table 115 Middle East & Africa Sevoflurane Market Outlook, By Maintenance of Anesthesia (2024-2032) ($MN)
• Table 116 Middle East & Africa Sevoflurane Market Outlook, By End User (2024-2032) ($MN)
• Table 117 Middle East & Africa Sevoflurane Market Outlook, By Hospitals (2024-2032) ($MN)
• Table 118 Middle East & Africa Sevoflurane Market Outlook, By Ambulatory Surgical Centers (ASCs) (2024-2032) ($MN)
• Table 119 Middle East & Africa Sevoflurane Market Outlook, By Specialty Clinics (2024-2032) ($MN)
• Table 120 Middle East & Africa Sevoflurane Market Outlook, By Other Healthcare Facilities (2024-2032) ($MN)

According to Stratistics MRC, the Global Sevoflurane Market is accounted for $476.1 million in 2025 and is expected to reach $739.9 million by 2032 growing at a CAGR of 6.5% during the forecast period. Sevoflurane is a volatile, inhalational anesthetic widely used for inducing and maintaining general anesthesia. It is a colorless, non-flammable liquid with a sweet odor, making it ideal for pediatric and adult patients. Known for its rapid onset and recovery, sevoflurane provides smooth induction with minimal airway irritation. It has a low blood-gas partition coefficient, allowing quick adjustments in anesthesia depth. While generally well-tolerated, it can cause dose-dependent hypotension and rare nephrotoxicity.

According to the World Journal of Surgery published in 2021, 3646 operations were conducted to satisfy the surgical requirements of the population in India.

Market Dynamics:

Driver:

Increasing Surgical Procedures

The growing number of surgical procedures worldwide is propelling considerable growth in the sevoflurane market. Sevoflurane is a popular inhalation anesthetic that is used in hospitals and ambulatory surgery centers due to its quick induction and recovery times. Demand is also being increased by the growing incidence of chronic illnesses, improvements in less invasive surgery, and the development of a larger healthcare system. Sevoflurane's vital function in contemporary anesthetic methods is further supported by the market's expansion due to the aging population's increased need for surgical procedures.

Restraint:

High Cost Compared to Alternatives

The high cost of sevoflurane compared to alternative anesthetics significantly hinders its market growth. Healthcare facilities, especially in cost-sensitive regions, may opt for lower-cost substitutes like isoflurane or desflurane, limiting sevoflurane adoption. This cost barrier affects procurement decisions, particularly in developing markets, reducing its overall demand. Additionally, price-conscious hospitals and clinics may restrict its usage, impacting sales and revenue growth for manufacturers.

Opportunity:

Advancements in Anesthesia Technology

Advancements in anesthesia technology are driving significant growth in the market, enhancing patient safety, precision, and efficiency in surgeries. Innovations such as automated anesthesia delivery, real-time monitoring, and low-flow techniques optimize Sevoflurane usage, reducing wastage and side effects. The rise of minimally invasive procedures and improved vaporizers further boost demand. Additionally, enhanced pharmacokinetics and better recovery profiles make Sevoflurane the preferred choice for anesthetists. These advancements collectively fuel market expansion, ensuring safer and more effective anesthesia administration worldwide.

Threat:

Potential Adverse Effects

The Sevoflurane market faces potential adverse effects due to regulatory restrictions, supply chain disruptions, and health concerns. Stringent environmental regulations on volatile anesthetics hinder market expansion. Supply chain volatility, including shortages of raw materials, affects production and pricing. Additionally, concerns over neurotoxicity in pediatric and elderly patients raise safety issues, leading to reduced adoption. Rising competition from alternative anesthetics and increasing preference for total intravenous anesthesia (TIVA) further restrict market growth and profitability.

Covid-19 Impact:

The COVID-19 pandemic had a mixed impact on the sevoflurane market. While elective surgeries declined due to lockdowns, the demand for Sevoflurane surged in critical care settings, particularly for ventilated COVID-19 patients. Supply chain disruptions and hospital resource reallocation initially slowed market growth, but post-pandemic recovery, increased surgical procedures, and improved healthcare infrastructure have driven a strong resurgence in demand across the industry.

The hospitals segment is expected to be the largest during the forecast period

The hospitals segment is expected to account for the largest market share during the forecast period as these facilities are primary users of the anesthetic for surgical procedures. With rising surgical volumes, increasing healthcare infrastructure, and advancements in anesthesia techniques, hospitals are boosting demand for Sevoflurane. Additionally, the growing prevalence of chronic diseases requiring surgical interventions further fuels market growth. The segment benefits from strong adoption due to its effectiveness, safety profile, and widespread use in general anesthesia, reinforcing its positive impact on market expansion.

The high purity sevoflurane segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the high purity sevoflurane segment is predicted to witness the highest growth rate due to its superior efficacy, safety, and reduced side effects in anesthesia applications. With increasing surgical procedures and rising demand for minimally invasive treatments, hospitals and clinics are prioritizing high-purity formulations for better patient outcomes. Additionally, stringent regulatory standards and advancements in pharmaceutical manufacturing are ensuring consistent quality, further boosting market adoption.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share due to an increase in surgical operations, technological developments in anesthetic, and growing healthcare expenditures. Sevoflurane is the recommended option for inhalation anesthetic because to its effectiveness, quick recovery period, and few side effects. Demand is also fueled by an aging population and the rising incidence of chronic diseases. Its popularity is further aided by continuous research and development in anesthetic administration technologies. This market expansion adds to the region's cutting-edge healthcare infrastructure and guarantees better patient results.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR because of an increase in surgical operations, a growing healthcare infrastructure, and technological breakthroughs in anesthetic. By offering safer and more effective inhalation anesthetic, the market is improving patient outcomes. Demand is further fueled by an aging population, growing medical tourism, and hospital development. Sevoflurane is a major factor in raising surgical effectiveness and general healthcare standards in the area, and government programs to improve healthcare accessibility also support market growth.

Key players in the market

Some of the key players in Sevoflurane Market include AbbVie Inc., Accord Healthcare, AstraZeneca, Baxter International Inc., Beijing Zizhu Pharmaceutical Co., Ltd., Endo International plc, Fresenius Kabi AG, Hikma Pharmaceuticals PLC, Hospira Inc., Jiangsu Hengrui Pharmaceuticals Co., Ltd., Lunan Pharmaceutical Group Co., Ltd., Maruishi Pharmaceutical Co., Ltd., Merck KGaA, Piramal Critical Care, Shandong Keyuan Pharmaceutical Co., Ltd., Shanghai Huayuan Ethylene Co., Ltd. and Troikaa Pharmaceuticals Ltd.

Key Developments:

In March 2025, AstraZeneca and Alteogen Inc. have entered into an exclusive license agreement for ALT-B4, a novel hyaluronidase utilising Hybrozyme(TM) platform technology. Under the terms of the agreement, AstraZeneca will acquire worldwide rights to use ALT-B4 to develop and commercialise subcutaneous formulations of several oncology assets.

In February 2024, AstraZeneca has entered into a definitive agreement to acquire Fusion Pharmaceuticals Inc., a clinical-stage biopharmaceutical company developing next-generation radioconjugates (RCs). The acquisition marks a major step forward in AstraZeneca delivering on its ambition to transform cancer treatment and outcomes for patients by replacing traditional regimens like chemotherapy and radiotherapy with more targeted treatments.

Products Covered:

• Generic Sevoflurane
• Branded Sevoflurane

Formulations Covered:

• Standard Purity Sevoflurane
• High Purity Sevoflurane

Distribution Channels Covered:

• Direct Sales
• Distributors/Wholesalers
• Online Pharmacies
• Retail Pharmacies

Applications Covered:

• Induction of Anesthesia
• Maintenance of Anesthesia

End Users Covered:

• Hospitals
• Ambulatory Surgical Centers (ASCs)
• Specialty Clinics
• Other Healthcare Facilities

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 Product Analysis
• 3.7 Application Analysis
• 3.8 End User Analysis
• 3.9 Emerging Markets
• 3.10 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Sevoflurane Market, By Product

• 5.1 Introduction
• 5.2 Generic Sevoflurane
• 5.3 Branded Sevoflurane

6 Global Sevoflurane Market, By Formulation

• 6.1 Introduction
• 6.2 Standard Purity Sevoflurane
• 6.3 High Purity Sevoflurane

7 Global Sevoflurane Market, By Distribution Channel

• 7.1 Introduction
• 7.2 Direct Sales
• 7.3 Distributors/Wholesalers
• 7.4 Online Pharmacies
• 7.5 Retail Pharmacies

8 Global Sevoflurane Market, By Application

• 8.1 Introduction
• 8.2 Induction of Anesthesia
• 8.3 Maintenance of Anesthesia

9 Global Sevoflurane Market, By End User

• 9.1 Introduction
• 9.2 Hospitals
• 9.3 Ambulatory Surgical Centers (ASCs)
• 9.4 Specialty Clinics
• 9.5 Other Healthcare Facilities

10 Global Sevoflurane Market, By Geography

• 10.1 Introduction
• 10.2 North America
  • 10.2.1 US
  • 10.2.2 Canada
  • 10.2.3 Mexico
• 10.3 Europe
  • 10.3.1 Germany
  • 10.3.2 UK
  • 10.3.3 Italy
  • 10.3.4 France
  • 10.3.5 Spain
  • 10.3.6 Rest of Europe
• 10.4 Asia Pacific
  • 10.4.1 Japan
  • 10.4.2 China
  • 10.4.3 India
  • 10.4.4 Australia
  • 10.4.5 New Zealand
  • 10.4.6 South Korea
  • 10.4.7 Rest of Asia Pacific
• 10.5 South America
  • 10.5.1 Argentina
  • 10.5.2 Brazil
  • 10.5.3 Chile
  • 10.5.4 Rest of South America
• 10.6 Middle East & Africa
  • 10.6.1 Saudi Arabia
  • 10.6.2 UAE
  • 10.6.3 Qatar
  • 10.6.4 South Africa
  • 10.6.5 Rest of Middle East & Africa

11 Key Developments

• 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 11.2 Acquisitions & Mergers
• 11.3 New Product Launch
• 11.4 Expansions
• 11.5 Other Key Strategies

12 Company Profiling

• 12.1 AbbVie Inc.
• 12.2 Accord Healthcare
• 12.3 AstraZeneca
• 12.4 Baxter International Inc.
• 12.5 Beijing Zizhu Pharmaceutical Co., Ltd.
• 12.6 Endo International plc
• 12.7 Fresenius Kabi AG
• 12.8 Hikma Pharmaceuticals PLC
• 12.9 Hospira Inc.
• 12.10 Jiangsu Hengrui Pharmaceuticals Co., Ltd.
• 12.11 Lunan Pharmaceutical Group Co., Ltd.
• 12.12 Maruishi Pharmaceutical Co., Ltd.
• 12.13 Merck KGaA
• 12.14 Piramal Critical Care
• 12.15 Shandong Keyuan Pharmaceutical Co., Ltd.
• 12.16 Shanghai Huayuan Ethylene Co., Ltd.
• 12.17 Troikaa Pharmaceuticals Ltd. .